Status:
RECRUITING
AQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON Database
Lead Sponsor:
AstraZeneca
Collaborating Sponsors:
Hospitalidee
Hospitalidee has been asserted to be a valid organization name by UHToulouse
Conditions:
Chronic Lymphocytic Leukemia
Eligibility:
All Genders
Brief Summary
QoL is often not assessed in real-world studies; hence, there is limited understanding about the real-world QoL of patients diagnosed with CLL. Besides, studies evaluating QoL have largely focused on ...
Detailed Description
PROTOCOL SYNOPSIS Background/Rationale: CLL is the most prevalent leukemia among adults. The estimated incidence of CLL was 4 674 in 2018 in France, 59% in men with a median age of 71 in men and 73 ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- The following patients will be eligible for inclusion in the AQUALIS study :
- Patient enrolled in the PLATON database
- Patient ≥18 years old
- Treatment naïve CLL patient treated with acalabrutinib in a real life setting. Treatment pattern is Acala mono or Acala + Obinutuzumab
- Patient who do not object to his health data collected in PLATON study being re-use for analysis/research purpose
- Patients who started Acala but discontinued before 12 months are also included.
- Exclusion criteria:
- Pregnant women
- Patients under protection of justice
- Patients over the age of 18 and unable to express their non-opposition
- Patients with prior CLL treatments
Exclusion
Key Trial Info
Start Date :
April 28 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT06548152
Start Date
April 28 2025
End Date
December 31 2025
Last Update
October 27 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Saint-Affrique, France